Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Modalis Therapeutics Corporation ( (JP:4883) ) has provided an update.
Modalis Therapeutics Corporation reported its consolidated financial results for the first half of 2025, showing a continued loss with an operating income of negative 1,031 million yen. Despite the financial challenges, the company maintains a strong capital adequacy ratio of 92.5%, indicating a stable financial position. The company has not provided earnings forecasts for the fiscal year 2025 due to uncertainties in formulating accurate estimates.
More about Modalis Therapeutics Corporation
Modalis Therapeutics Corporation is a biotechnology company listed on the Tokyo Stock Exchange, focusing on developing innovative therapeutics. The company specializes in gene therapy and aims to address genetic disorders through its proprietary technology.
Average Trading Volume: 5,097,750
Technical Sentiment Signal: Sell
Current Market Cap: Yen7.08B
For detailed information about 4883 stock, go to TipRanks’ Stock Analysis page.